# US 2020/0369703 A1 · Modified oligonucleotides and compound that can be used for synthesizing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369703 A1
- Document ID: US20200369703A1
- Status: Published application
- Kind: A1
- Application number: 16/756,855
- Filed: 2017-12-26
- Published: 2020-11-26
- Earliest claimed: 2017-12-26
- Assignees: Guangzhou Ribobio Co., Ltd.
- Applicants: Guangzhou Ribobio Co., Ltd.
- Inventors: Biliang ZHANG; Wei WANG
- Web page: https://patentgrep.com/patent/US20200369703A1

## CPC

- C07H 15/04: attached to an oxygen atom of the saccharide radical
- A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C07H 1/00: Processes for the preparation of sugar derivatives
- C07H 15/08: Polyoxyalkylene derivatives
- C07H 15/12: attached to a nitrogen atom of the saccharide radical
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H 21/02: with ribosyl as saccharide radical
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/351: Conjugate
- C12N 2330/30: chemically synthesised
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure falls within the field of biomedical technology, and in particular relates to modified oligonucleatides and a compound that can be used for synthesizing same and a method for modifying oligonucleotides. The present disclosure also relates to the use of the modified oligonucleotides for preventing and/or treating diseases associated with the liver in a subject.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

A compound having a general formula of Ax-linker-R, wherein Ax is a ligand, linker is a linker arm, and R is selected from R1, R2, R3 or R4,
wherein Ax is a ligand of a human asialoglycoprotein receptor (ASGPR),
R1 is
wherein, Z is a protecting group for hydroxy, preferably 4, 4-dimethoxytriphenylalkyl (DMTr) or 4-methoxytriphenylchloromethyl (MMT);
R2 is
and wherein, m1, and m2 are each independently selected from integers between 1 and 10, and Z is a protecting group for hydroxy, preferably 4, 4-dimethoxytriphenylmethyl (DMTr) or 4-methoxytriphenylchloromethyl (MMT);
R3 is
R4 is

### Claim 33 (depends on 32)

The compound of claim 32, wherein Ax is galactose, acetylgalactosamine, a galactose-containing polysaccharide, an acetylgalactosamine-containing polysaccharide, a galactose derivative (e.g., an ester of galactose, such as galactoacetate), or an acetylgalactosamine derivative (e.g., an ester of acetylgalactosamine, such as acetylgalactosamine acetate);
optionally, Ax is also provided with a modifying group, such as a carbonylalkyl group or an esteralkyl group, an alkyl portion of the carbonylalkyl group or the esteralkyl group is preferably a C1-6 alkyl or a C6-12 alkyl;
preferably, Ax is selected from:

### Claim 34 (depends on 32)

The compound of claim 32, wherein the structure of the linker is shown in formula (i), (ii), (iii), (iv), or (v):
wherein n is selected from an integer between 1 and 10, preferably n is 1 or 6;
wherein n1 and n2 are each independently selected from an integer between 1 and 10, preferably n1 is 1, preferably, n2 is 4;
wherein n1, n2 and n3 are each independently selected from an integer between 1 and 10, preferably n1 is 1, preferably n2 is 3, preferably, n3 is 4;
wherein n is selected from an integer between 1-10, preferably n is 1; and
wherein n is selected from an integer between 1-10, preferably n is 4.

### Claim 35 (depends on 34)

The compound of claim 34 having one of the following characteristics:
(1) R is R1, R2, or R3, Ax is A1, A2, or A3, the structure of the linker is shown in formula (i);
(2) R is R1 or R2, Ax is A1, and the structure of the linker is shown in formula (ii);
(3) R is R1, Ax is A1, and the structure of the linker is shown in formula (iii);
(4) R is R1, Ax is A1, and the structure of the linker is shown in formula (iv); and
(5) R is R4, Ax is A1 and the structure of the linker is shown in formula (v);
preferably, in the linker shown in formula (i), n is 1 or 6;
preferably, in the linker shown in formula (ii), n1 is 1 and n2 is 4;
preferably, in the linker shown in formula (iii), n1 is 1, n2 is 3 and n3 is 4; and
preferably, in the linker shown in formula (iv), n is 1,
preferably, in the linker shown in formula (v), n is 4; and
preferably, the compound is selected from
wherein n is selected from an integer between 1 and 10,
wherein n1 and n2 are each independently selected from integers between 1 and 10,
wherein n1, n2 and n3 are each independently selected from integers between 1 and 10;
wherein n, m1, and m2 are each independently selected from integers between 1 and 10,
wherein n1, n2, m1, and m2 are each independently selected from integers between 1 and 10, and
wherein n1, n2, n3, m1, and m2 are each independently selected from integers between 1 and 10.

### Claim 36 (depends on 32)

A compound comprising an oligonucleotide and a conjugate group, wherein the modified oligonucleotide has a general formula
wherein PN is the oligonucleotide, Y is selected from an integer between 1 and 10, X is selected from an integer between 0 and 10, MT is selected from a conjugate group as shown in formulas (1), (2), (3), and (4), when X is not O, X M are each independently selected from a conjugate group represented by formula (1′), (2′), and (3′),
wherein Ax is a ligand, linker is a linker arm, and Q is a hydroxyl group or a modifier; and
wherein the conjugate group represented by formulas (1)-(4) and formula (1′), (2′), and (3′) are derived from the compound having a general formula of Ax-linker-R as claimed in claim 32,
wherein the Ax in any one of the formulas (1)-(4) and formula (1′), (2′), and (3′) is the same with the Ax in the compound having a general formula of Ax-linker-R as claimed in claim 32, and the linker in any one of the formulas (1)-(4) and formula (1′), (2′), and (3′) is the same with the linker in the compound having a general formula of Ax-linker-R as claimed as in claim 32, and the rest portion in any one of the formulas (1)-(4) and formula (1′), (2′), and (3′) is derived from R of the compound having a general formula of Ax-linker-R as claimed in claim 32.

### Claim 37 (depends on 36)

The compound of claim 36, in the conjugate groups represented by formulas (1)-(3), and formula (1′)-(3′), Q is selected from: cholesterol and derivatives thereof, polyethylene glycol, fluorescent probes, biotin, polypeptides, vitamins and tissue targeting molecules.

### Claim 38 (depends on 36)

The compound of claim 36, wherein the oligonucleotide is a single-stranded oligonucleotide or a double-stranded oligonucleotide;
preferably, the oligonucleotide comprises one or more modified nucleotides;
preferably, the one or more modified nucleotides are each independently selected from: 2′-methoxyethyl modified nucleotides, 2′-O-alkyl modified nucleotides (e.g. 2′-O-methyl modified nucleotides), 2′-O-allyl modified nucleotides, 2′-C-allyl modified nucleotides, 2′-fluoro modified nucleotides, 2′-deoxy modified nucleotides, 2′-hydroxy modified nucleotides, locked nucleotides, unlocked nucleic acids, hexitol nucleic acids;
preferably, the modified nucleotide is selected from 2′-O-alkyl modified nucleotides, 2′-fluoro modified nucleotides;
preferably, the oligonucleotide is provided with a terminal modifier, preferably the terminal modifier is selected from: cholesterol, polyethylene glycol, fluorescent probes, biotin, polypeptides, vitamins, tissue targeting molecules and any combination thereof;
preferably, the phosphate-containing backbone of the oligonucleotide is modified, preferably the modification is a phosphorthioate modification;
preferably, the oligonucleotide is a siRNA;
preferably, the siRNA comprises a sense strand and an antisense strand complementary to form a double strand;
preferably, the siRNA comprises a sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.

### Claim 39 (depends on 36)

The compound of claim 36, wherein
is each independently linked to the 3′ terminal, 5′ terminal, or sequence middle of any strand of the oligonucleotide;
preferably,
is linked to the oligonucleotide via a phosphotriester;
preferably, the linkage between M and MT or between M and M is via a phosphotriester.

### Claim 40 (depends on 36)

The compound of claim 36, wherein the oligonucleotide is a single-stranded oligonucleotide;
preferably, Y is 1,
is linked to the 3′ terminal or 5′ terminal of the oligonucleotide;
preferably, Y is 2, and 2
are each linked to the 3′ terminal and 5′ terminal of the oligonucleotide.

### Claim 41 (depends on 36)

The compound of claim 36, wherein the oligonucleotide is a double-stranded oligonucleotide;
preferably, Y is 1,
is linked to either the 3′ terminal or 5′ terminal of any of the strands in the oligonucleotide;
preferably, Y is 2, 2
are each linked to the 3′ terminal and 5′ terminal of the same strand in the oligonucleotide;
preferably, Y is 2, 2
are each linked to the 3′ terminals of two strands in the oligonucleotide;
preferably, Y is 2, 2
are each linked to the 5′ terminals of two strands in the oligonucleotide;
preferably, Y is 3, two of the 3
are respectively linked with the 3′ terminal and 5′ terminal of the same strand in the oligonucleotide, and the third is linked with the 3′ terminal or 5′ terminal of the other strand;
preferably, Y is 4, 4
are each linked to the 3′ terminals and 5′ terminals of two strands in the oligonucleotide.

### Claim 42 (depends on 36)

The compound of claim 36, wherein X is not 0, MT and at least one M have the same Ax and/or linker structure;
preferably, X is greater than 1, and X M have the same or different structures;
preferably, Y is greater than 1 and Y
have the same or different structures.

### Claim 43 (depends on 36)

The compound of claim 36, wherein Y is 1, X is 0, and the compound has one of the following characteristics:
(1) the structure of MT is shown in formula (1), Ax is A1′, A2′ or A3′, and the structure of the linker is shown in formula (i);
(2) the structure of MT is shown in formula (1), Ax is A1′, and the structure of the linker is shown in formula (ii);
(3) the structure of MT is shown in formula (1), Ax is A1′, and the structure of the linker is shown in formula (iii);
(4) the structure of MT is shown in formula (1), Ax is A1′, and the structure of the linker is shown in formula (iv);
(5) the structure of MT is shown in formula (2), Ax is A1′, A2′ or A3′, and the structure of the linker is shown in formula (i);
(6) the structure of MT is shown in formula (2), Ax is A1′, and the structure of the linker is shown in formula (ii);
(7) the structure of MT is shown in formula (3), Ax is A1′, A2′ or A3′, and the structure of the linker is shown in formula (i);
(8) the structure of MT is shown in formula (4), Ax is A1′, and the structure of the linker is shown in formula (v); and
(9) the structure of MT is shown in formula (2), Ax is A1′, and the structure of the linker is shown in formula (iii);
preferably, in the linker shown in formula (i), n is 1 or 6;
preferably, in the linker shown in formula (ii), n1 is 1 and n2 is 4;
preferably, in the linker shown in formula (iii), n1 is 1, n2 is 3 and n3 is 4; and
preferably, in the linker shown in formula (iv), n is 1.

### Claim 44 (depends on 36)

The compound of claim 36, wherein Y is 1, X is 1, 2, or 3, when X is 2 or 3, each M has the same structure, and the compound has one of the following characteristics:
(1) the structure of M is shown in formula (1′), Ax is A1′, and the structure of the linker is shown in formula (i); and the structure of MT is shown in formula (1), Ax is A1′, and the structure of the linker is shown in formula (i);
(2) the structure of M is shown in formula (1′), Ax is A1′, and the structure of the linker is shown in formula (ii); and the structure of MT is shown in formula (1), Ax is A1′, and the structure of the linker is shown in formula (ii);
(3) the structure of M is shown in formula (1′), Ax is A1′, and the structure of the linker is shown in formula (iii); and the structure of MT is shown in formula (1), Ax is A1′, and the structure of the linker is shown in formula (iii);
(4) the structure of M is shown in formula (2′), Ax is A1′, and the structure of the linker is shown in formula (i); and the structure of MT is shown in formula (2), Ax is A1′, and the structure of the linker is shown in formula (i);
(5) the structure of M is shown in formula (1′), Ax is A1′, and the structure of the linker is shown in formula (ii); and the structure of MT is shown in formula (1), Ax is A1′, and the structure of the linker is shown in formula (ii); and
(6) the structure of M is shown in formula (1′), Ax is A3′, and the structure of the linker is shown in formula (ii); and the structure of MT is shown in formula (1), Ax is A3′, and the structure of the linker is shown in formula (ii);
preferably, in the linker shown in formula (i), n is 1 or 6;
preferably, in the linker shown in formula (ii), n1 is 1 and n2 is 4; and
preferably, in the linker shown in formula (iii), n1 is 1, n2 is 3 and n3 is 4.

### Claim 45 (depends on 36)

The compound of claim 36, wherein Y is 1, X is 2, the structure of the two M are the same as shown in formula (1′), Ax is A1′, and the structure of the linker is shown in formula (iv); the structure of MT is shown in formula (4), Ax is A1′, and the structure of the linker is shown in formula (v); and
preferably, in the linker shown in formula (iv), n is 1.

### Claim 46 (depends on 36)

The compound of claim 36, the compound is selected from:
Wherein n1, n2, n3 and n are each independently selected from integers between 1 and 10.

### Claim 47 (depends on 32)

A kit comprising the compound as claimed in claim 32;
preferably, the kit further comprises a reagent for the synthesis and/or modification of an oligonucleotide.

### Claim 48 (depends on 36)

A pharmaceutical composition comprising the modified oligonucleotide as claimed in claims 36, and optionally a pharmaceutically acceptable carrier.
preferably, the pharmaceutical composition is used for the prevention and/or treatment of a liver-related disease in a subject;
preferably, the liver-related disease is selected from: hereditary angioedema, familial tyrosinemia type I, Alagille syndrome, α-1-antitrypsin deficiency, bile acid synthesis and metabolic defects, biliary atresia, cystic fibrosis liver disease, idiopathic neonatal hepatitis, mitochondrial liver disease, progressive familial intrahepatic cholestasis, primary sclerosing cholangitis, transthyretin amyloidosis, hemophilia, homozygous familial hypercholesterolemia, hyperlipidemia, steatohepatitis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), hyperglycemia and diseases involving abnormally increased hepatic glucose production similar to type II diabetes, hepatitis, hepatic porphyrins.

### Claim 49 (depends on 32, 40)

A method for modifying an oligonucleotide, comprising linking one or more compounds to the oligonucleotide, wherein the one or more compounds are each independently selected from the compound as claimed in claim 32;
preferably, in the method, the linking is achieved by a chemical reaction of the
on the compound;
preferably, the oligonucleotide is as defined in claim 40;
preferably, the method is used for solid phase synthesis.

### Claim 50 (depends on 32, 49)

The method of claim 49, comprising:
step (1): providing an oligonucleotide and linking a first compound to the oligonucleotide to obtain a conjugate M-containing oligonucleotide, the first compound is selected from the compound when R is R1, R2, or R3, as defined in claim 32; and
step (2): linking a second compound to the conjugate M formed in the previous step, the second compound is selected from the compound of claim 32.

### Claim 51 (depends on 50)

The method of claim 50, the method further comprises step (3): repeating step (2) one or more times (e.g., 2-9 times);
optionally, the method further comprises step (4): repeating step (1), step (2), and step (3) one or more times (e.g., 2-9 times);
preferably, in the steps (1) and (2), the linking is achieved by a chemical reaction of the
on the first compound or the second compound.
